DUBLIN, April 10, 2015 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/5hfjqq/global_acute) has announced the addition of the"Global Acute Coronary Syndrome (ACS) Market 2015-2019" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The Global ACS market to grow at a CAGR of 13.24% over the period 2014-2019
ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.
The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.
Growing public awareness of ACS is one of the key trends being witnessed in this market. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks.
According to the report, the elderly population, from middle-aged and older, are more prone to developing ACS because with aging, plaque accumulates in the arteries, resulting in the narrowing of the arterial passage and difficulty in blood flow to the heart.
Further, the report states that patent expiry of a drug results in the loss of the exclusive market for that particular drug, thus leading to a rapid decline in its sales. Patent expiry of a drug results in the loss of the exclusive market, resulting in a rapid decline in the sales of that particular drug.
Key Vendors
- Astra Zeneca
- BMS
- Eli Lilly
- GSK
- Sanofi
Other Prominent Vendors
- AbbVie
- Amgen
- Bayer
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Portola Pharmaceuticals
- Teva Pharmaceutical
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Market Research Methodology
- Introduction
- Disease Overview
- ACS Pipeline Landscape
- Market Landscape
- Market Segmentation by ECG Output
- Geographical Segmentation
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and their Impact
- Vendor Landscape
- Key Vendor Analysis
For more information visithttp://www.researchandmarkets.com/research/5hfjqq/global_acute
Media Contact:Laura Wood , +353-1-481-1716, press@researchandmarkets.net
